Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-11-15
2008-12-09
Stockton, Laura L. (Department: 1626)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C548S304700, C514S394000
Reexamination Certificate
active
07462724
ABSTRACT:
Compounds of Formula (I)inhibit the PARP enzyme and are useful for treating a disease or a disorder associated with PARP. Also disclosed are pharmaceutical compositions comprising compounds of Formula (I), methods of treatment comprising compounds of Formula (I), and methods of inhibiting the PARP enzyme comprising compounds of Formula (I).
REFERENCES:
patent: 6696437 (2004-02-01), Lubisch et al.
patent: 3522230 (1987-01-01), None
patent: 19916460 (2000-10-01), None
patent: 19920936 (2000-11-01), None
patent: 200141067 (2002-05-01), None
patent: 09704771 (1997-02-01), None
patent: 9839343 (1998-09-01), None
patent: 0029384 (2000-05-01), None
patent: 0032579 (2000-06-01), None
patent: 0121615 (2001-03-01), None
patent: 0182877 (2001-11-01), None
patent: 02068407 (2002-09-01), None
patent: 03020698 (2003-03-01), None
patent: 03106430 (2003-12-01), None
patent: 2004065370 (2004-08-01), None
patent: 2004096793 (2004-11-01), None
patent: 0026192 (2008-05-01), None
Burkart, V., et al., “Mice lacking the poly(ADP-ribose) polymerase gene are resistant to pancreatic beta-cell destruction and diabetes development induced by streptozocin”, Nature Medicine, vol. 5, No. 3, pp. 314-319, 1999.
Chen, G., et al., “Potentiation of the antitumor activity of cisplatin in mice by 3-aminobenzamide and nicotinamide”, Cancer Chemotherapy and Pharmacology, vol. 22, No. 4, pp. 303-307, 1988.
Cuzzocrea, S., et al., “Protective effects of 3-aminobenzamide, an inhibitor of poly (ADP-ribose) synthase in a carrageenan-induced model of local inflammation”, European Journal of Pharmacology, vol. 342, pp. 67-76, 1998.
Ehrlich, W., et al., “Inhibition of the induction of collagenase by interleukin-1 β in cultured rabbit synovial fibroblasts after treatment with the poly(ADP-ribose)-polymerase inhibitor 3-aminobenzamide”, Rheumatology International, vol. 15, pp. 171-172, 1995.
Kröger, H., et al., “Synergistic effects of thalidomide and poly(ADP-rose) polymerase inhibition on type Ii collagen-induced arthristis in mice”, Inflammation, vol. 20, No. 2, pp. 203-215, 1996.
Prescott, et al., “Methods in Cell Biology,” Academic Press, Inc, vol. XIV, pp. 33-71, 1976.
Szabó, C., et al., “Protection against peroxynitrite-induced fibroblast injury and arthritis, development by inhibition of poly(ADP-ribose) synthase”, Proceedings of the National Academy of Sciences, vol. 95, pp. 3867-3872, 1998.
Thiemermann, C., et al., “Inhibition of the activity of poly(ADP ribose) synthetase reduces ischemia-reperfusion injury in the heart and skeletal muscle”, Proceedings of the National Academy of Sciences, vol. 94, No. 2, pp. 679-683, 1997.
Weltin, D., et al., “Immunosuppressive Activities of 6(5H)-Phenanthridinone, A new Poly(ADP-Ribose)Polymerase Inhibitor,” Int. J. Immunopharmac, vol. 17, No. 4, pp. 265-271, 1995.
White, A., et al., “Ptentiation of cytotoxic drug activity in human tumour cell lines, by amine-substituted 2-arylbenzimidazole-4-carboxamilde PARP-1 inhibitors,” Bioorganic & Medicinal Chemistry Letters, vol. 14, No. 10, pp. 2433-2437, 2004.
Alexy, et al., “Inhibition of ADP-evoked platelet aggregation by selected poly(ADP-ribose)polymerase inhibitors”, J Of Cardiovascular Pharm, 43(3), 423-431 (2004).
Gilchrist, “Cyclisation of Ortho-Substituted N-Arylbenzimidoyl Nitrenes, Part 2.1 Preferential Cyclizations at an Ortho-Position Bearing a Methoxycarbonyl Group”, J of Chem Soci, Pekin Transactions 1, GB, Chemical Society. Letchworth, 2303-2307 (1979).
Griffin, et al., “Resistance Modifying Agents 3 Navel Benzimidazole and quinnazolinone Inhibitors of the DNA Repair Enzyme Poly(ADP-ribose)polymerase”, Chemical Abstracts, 125(5), 43-47 (1996).
White, et al., “Potentiation of cytotoxic drug activity in human tumor cell lines, by amine-substituted 2-arylbenzimidazole-4carboxamide PARP-1 inhibitors”, Bioorganic 7 medicinal Chemistry Letters, 14(10), 2433-2437 (2004).
STN Database Registry No. 784127-26-0, Nov. 19, 2004.
STN Database Registry No. 765258-50-2, Oct. 19, 2004.
STN Database Registry No. 748757-37-1, Seo. 21, 2004.
STN Database Registry No. 747397-72-4, Sep. 19, 2004.
STN Database Registry No. 739354-38-2, Sep. 5, 2004.
STN Database Registry No. 738569-62-5, Sep. 3, 2004.
STN Database Registry No. 687630-59-7, May 31, 2004.
Gandhi Viraj B.
Giranda Vincent L.
Gong Jianchun
Penning Thomas D.
Thomas Sheela A.
Abbott Laboratories
Polster Rachel A.
Stockton Laura L.
LandOfFree
Substituted 1H-benzimidazole-4-carboxamides are potent PARP... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted 1H-benzimidazole-4-carboxamides are potent PARP..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted 1H-benzimidazole-4-carboxamides are potent PARP... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4028474